Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Department of Gastrointestinal Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
JNCI Cancer Spectr. 2020 Oct 16;5(1). doi: 10.1093/jncics/pkaa093. eCollection 2021 Feb.
The American Joint Committee on Cancer (AJCC) 8th tumor-node-metastasis (TNM) classification for colorectal cancer (CRC) has limited ability to predict prognosis.
We included 45 379 eligible stage I-III CRC patients from the Surveillance, Epidemiology, and End Results Program. Patients were randomly assigned individually to a training (n=31 772) or an internal validation cohort (n=13 607). External validation was performed in 10 902 additional patients. Patients were divided according to T and N stage permutations. Survival analyses were conducted by a Cox proportional hazard model and Kaplan-Meier analysis, with T1N0 as the reference. Area under receiver operating characteristic curve and Akaike information criteria were applied for prognostic discrimination and model fitting, respectively. Clinical benefits were further assessed by decision curve analyses.
We created a modified TNM (mTNM) classification: stages I (T1-2N0-1a); IIA (T1N1b, T2N1b, T3N0); IIB (T1-2N2a-2b, T3N1a-1b, T4aN0); IIC (T3N2a, T4aN1a-2a, T4bN0); IIIA (T3N2b, T4bN1a); IIIB (T4aN2b, T4bN1b); and IIIC (T4bN2a-2b). In the internal validation cohort, compared with the AJCC 8th TNM classification, the mTNM classification showed superior prognostic discrimination (area under receiver operating characteristic curve = 0.675 vs 0.667, respectively; 2-sided <.001) and better model fitting (Akaike information criteria = 70 937 vs 71 238, respectively). Similar findings were obtained in the external validation cohort. Decision curve analyses revealed that the mTNM had superior net benefits over the AJCC 8th TNM classification in the internal and external validation cohorts.
The mTNM classification provides better prognostic discrimination than AJCC 8th TNM classification, with good applicability in various populations and settings, to help better stratify stage I-III CRC patients into prognostic groups.
美国癌症联合委员会(AJCC)第 8 版结直肠癌(CRC)肿瘤-淋巴结-转移(TNM)分期系统对预后的预测能力有限。
我们纳入了来自监测、流行病学和最终结果(SEER)计划的 45379 例符合条件的 I-III 期 CRC 患者。患者被随机分为训练队列(n=31772)和内部验证队列(n=13607)。另外 10902 例患者进行了外部验证。根据 T 和 N 分期的排列对患者进行分组。采用 Cox 比例风险模型和 Kaplan-Meier 分析进行生存分析,以 T1N0 作为参考。应用接受者操作特征曲线下面积和赤池信息量准则分别进行预后区分度和模型拟合评估。进一步通过决策曲线分析评估临床获益。
我们创建了改良 TNM(mTNM)分期:I 期(T1-2N0-1a);IIA 期(T1N1b、T2N1b、T3N0);IIB 期(T1-2N2a-2b、T3N1a-1b、T4aN0);IIC 期(T3N2a、T4aN1a-2a、T4bN0);IIIA 期(T3N2b、T4bN1a);IIIB 期(T4aN2b、T4bN1b);和 IIIC 期(T4bN2a-2b)。在内部验证队列中,与 AJCC 第 8 版 TNM 分期相比,mTNM 分期显示出更好的预后区分度(受试者工作特征曲线下面积分别为 0.675 和 0.667,双侧<.001)和更好的模型拟合(赤池信息量准则分别为 70937 和 71238,双侧<.001)。在外部验证队列中也得到了类似的发现。决策曲线分析显示,mTNM 分期在内部和外部验证队列中的净获益优于 AJCC 第 8 版 TNM 分期。
mTNM 分期比 AJCC 第 8 版 TNM 分期提供了更好的预后区分度,具有良好的适用性,可帮助更好地将 I-III 期 CRC 患者分层为预后组。